DeCure for Autoimmune lymphoproliferative syndrome
DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for autoimmune lymphoproliferative syndrome — screening already-approved drugs against its 8-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAutoimmune lymphoproliferative syndrome maps to a 8-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for autoimmune lymphoproliferative syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
NRAS proto-oncogene, GTPase (NRAS) — NRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ZIO · 1.55 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
The 2018 abstract on two cousins with autoimmune lymphoproliferative syndrome describes a family in which both cousins presented with infection. It mentions the therapeutic potential of sirolimus but provides no patient numbers, no response data, and no survival outcomes. No concrete results from sirolimus treatment are given.
A separate 2018 abstract discusses two patients with long-standing autoimmune diseases on immunosuppressants who developed aggressive lymphoproliferative disorders. Sustained regression occurred after simply stopping the immunosuppressive agents. This abstract does not involve sirolimus or autoimmune lymphoproliferative syndrome.
The 2010 abstract states that autoimmune lymphoproliferative syndrome is a rare group of disorders caused by genetic mutation affecting lymphocyte apoptosis. Clinical manifestations include lymphoproliferation, autoimmunity, and malignancies. It notes that no case had been reported in China at that time. No treatment data are provided.
What is still missing: any controlled trial of sirolimus in autoimmune lymphoproliferative syndrome, patient numbers sufficient to judge response, and stratification by genetic subtype.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Pediatrics International · 2018 · 7 citations · open access
Low‐dose sirolimus in two cousins with autoimmune lymphoproliferative syndrome‐associated infection
AbstractAutoimmune lymphoproliferative syndrome (ALPS) is characterized by non-malignant lymphoproliferation and autoimmunity, with a wide spectrum of clinical manifestations (OMIM 601859). Typical features include enlarged spleen and lymph nodes and autoimmune cytopenia. We describe a family with ALPS in which two cousins independently presented to their physicians with infection and discuss the therapeutic potential of sirolimus.
BMJ Case Reports · 2018 · 2 citations · open access
Treatment of advanced stage methotrexate-associated lymphoproliferative disorders (MTX-LPDs) with methotrexate discontinuation
AbstractWe present two cases of patient's with long-standing autoimmune diseases being treated with immunosuppressants that developed aggressive lymphoproliferative disorders. Immunosuppressants have a well-known association with disorders. Sustained regression of these lymphoproliferative disorders occurred with simple discontinuation of these immunosuppressive agents.
International journal of pediatrics · 2010 · 0 citations
Progress of autoimmune lymphoproliferactive syndrome
AbstractAutoimmune lymphoproliferactive syndrome is a rare group disorders associated with self stability and immune tolerance of lymphocyte due to genetic mutation which affects the lymphocyte apoptosis .The clinical manifestations comprise lymphoproliferation, development of autoimmunity and malignancies.The pathogenesis and clinical features are complex ALPS were easily missed and no case had been reported until now in China.
Key words:
Autoimmunity; Apoptosis; FAS gene; Double negative T cell
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
